Intercept Pharmaceuticals, Inc. (ICPT) Report Analysis
Corporate Events
Intercept Pharmaceuticals, Inc. Presents at The International Liver Congress 2022, Jun-22-2022 through Jun-25-2022
2022-06-21 11:30:00
Intercept Pharmaceuticals, Inc. Presents at The International Liver Congress 2022, Jun-22-2022 through Jun-25-2022. Venue: London, United Kingdom. Presentation Date(s): Jun-23-2022. Jun-24-2022. Jun-25-2022.
Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline
2022-06-06 10:30:00
Intercept Pharmaceuticals, Inc. announced an update on the timing of its pre-submission meeting with the U.S. Food and Drug Administration (FDA) regarding the potential resubmission of its nonalcoholic steatohepatitis (NASH) New Drug Application (NDA) based on an interim analysis of the REGENERATE trial in patients with fibrosis due to NASH. The pre-submission meeting, previously scheduled in June, has been moved to July following a recent request from the FDA that topline data from REGENERATE be provided to the agency for its review prior to the meeting. Intercept anticipates that topline data from REGENERATE will be available and made public in July.
Intercept Pharmaceuticals, Inc. Announces New Clinical Trial and Real-World Outcomes Data for Ocaliva in PBC
2022-06-03 11:30:00
Intercept Pharmaceuticals, Inc. announced results from two studies designed to evaluate clinical outcomes in patients with PBC on Ocaliva (obeticholic acid or OCA): COBALT, a Phase 3b/4 confirmatory clinical outcomes study, and HEROES-US, one of two HEROES real-world studies. Findings from these studies will be part of a broader evidence package being submitted to the U.S. Food and Drug Administration (FDA) in the second half of 2022. Ocaliva was granted an accelerated approval in 2016 based on a reduction in alkaline phosphatase (ALP), a blood marker of liver injury. COBALT was designed to determine rates of clinical events in patients with advanced PBC and was initiated to support post-marketing requirements. In 2021, Intercept announced COBALT would be terminated early as a result of conversations with regulatory authorities and guidance from the study's data monitoring committee (DMC). The DMC noted that the objectives of the trial were not feasible given the inherent challenges with enrolling and maintaining patients in a placebo-controlled study in a rare disease when the study drug is commercially available. Given this feedback, Intercept closed the trial and began to compile available data from COBALT. Intercept also initiated multiple real-world analyses, including the HEROES studies to provide greater insight into the impact of Ocaliva on clinical outcomes in patients with PBC. COBALT Study Results In COBALT, patients were randomized 1:1 to Ocaliva (n=168) or placebo (n=166). The primary endpoint, as agreed with the FDA, was time to first occurrence of any of the following clinical endpoints: all-cause death, liver transplant, or hospitalization for other serious liver-related events. The study did not demonstrate a statistically significant difference between Ocaliva and placebo on the primary endpoint: 71 subjects in the Ocaliva arm progressed to clinical events compared to 80 in the placebo arm (p=0.30; HR 0.84). The safety and tolerability of Ocaliva were consistent with its known profile; adverse events were in line with expectations for patients with advanced PBC based on the natural history of the disease. At the time of the early termination, COBALT was less than 80% enrolled. More than 50% of patients discontinued the study prior to meeting the study endpoint. In addition, at least 14% of patients on placebo initiated commercially available Ocaliva during the study but remained in the placebo arm for reporting purposes. The majority of patients in COBALT had advanced PBC and more than half (55%) would have been contraindicated for treatment with Ocaliva based on the current U.S. Prescribing Information. Given these factors, the data from COBALT could not provide a fulsome assessment of the impact of Ocaliva on clinical outcomes.
Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance
2022-06-02 20:06:00
On June 1, 2022, Gail Cawkwell, M.D., Ph.D., notified Intercept Pharmaceuticals, Inc. of her decision to resign from her position as the Company’s Senior Vice President, Medical Affairs, Safety & Pharmacovigilance, in order to pursue other opportunities. Dr. Cawkwell’s resignation was not the result of any disagreement regarding any matter related to the Company’s operations, policies or practices.
Intercept Pharmaceuticals, Inc. Presents at BIO International Convention 2022, Jun-13-2022
2022-05-14 02:46:00
Intercept Pharmaceuticals, Inc. Presents at BIO International Convention 2022, Jun-13-2022 . Venue: San Diego Convention Center, San Diego, California, United States. Speakers: Bijean Ford, Senior Manager of Regulatory Medical Writing.
Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis
2022-05-11 12:00:00
Intercept Pharmaceuticals, Inc. announced the first patient has been dosed in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC) who have not achieved an adequate biochemical response to ursodeoxycholic acid. The double-blind, randomized, active controlled, parallel group study will evaluate the reduction in alkaline phosphatase (ALP) over 12 weeks, followed by a long-term safety extension. The reduction in ALP has been accepted by regulators as part of a composite surrogate endpoint for investigational agents in PBC. Secondary endpoints include safety and tolerability, and other biochemical markers of disease progression: aspartate aminotransferase (AST), gamma-glutamyl transferase (GGT), alanine aminotransferase (ALT) and bilirubin. The study is expected to recruit approximately 60 patients, primarily in the U.S., across four treatment arms: BZF 100 mg + OCA placebo tablet once daily (QD), BZF 400 mg + OCA placebo tablet QD, BZF 100 mg + OCA 5 mg QD, BZF 400 mg + OCA 5 mg QD. A second Phase 2 study, currently active in Europe, is evaluating different dosing regimens of the OCA-BZF combination. A large Phase 1 study is ongoing in the U.S., testing multiple different dose combinations in healthy adult subjects. Once complete, these three complementary studies will inform dose selection and study design for a Phase 3 trial.
Mercury Pharma Group Limited signed a share purchase agreement to acquire 11 Foreign Subsidiaries of Intercept Pharmaceuticals, Inc. for $38.5 million.
2022-05-05 00:00:00
Mercury Pharma Group Limited signed a share purchase agreement to acquire 11 Foreign Subsidiaries of Intercept Pharmaceuticals, Inc. for $38.5 million on May 5, 2022. The transaction is subject to customary working capital and other adjustments. The parties expect that the completion of the transactions contemplated by the SPA and the other agreements will occur promptly after receipt of all required consents and approvals and the satisfaction of other customary closing conditions, including, without limitation, the approval of all foreign regulatory approvals. The SPA contains customary representations, warranties, and covenants of the parties. The purchaser has acquired a representation and warranty insurance policy that will be effective upon closing for claims for breaches of these representations and warranties. The SPA contains non-competition and non-solicitation covenants binding on the Company for three years prohibiting the Company from soliciting employees or establishing a competitive business in the Territory with respect to primary biliary cholangitis (“ PBC ”) or nonalcoholic steatohepatitis (“ NASH ”). The SPA also includes, among other things, customary interim operating covenants requiring the Company to continue operating in the ordinary course of business in the period between signing and closing. The sale of the shares of ICPT France will result in the transfer of the previously disclosed payback liability being negotiated by ICPT France and the French government. The purchase price under the SPA will be adjusted based on the estimated amount of the liability, which has been reserved in the Company’s consolidated financial statements, and the Company will recognize the transfer of the associated liability from its consolidated financial statements. Upon final resolution of the payback liability, ICPT Inc. will reimburse Advanz for any amount greater than the purchase price adjustment, or Advanz will reimburse ICPT Inc. for any amount less than the purchase price adjustment. The SPA may be terminated at any time prior to closing by either party if German, Austrian, Italian, and Spanish authorities do not provide (or are not deemed to provide) any regulatory approvals needed to consummate the share sale (the “ Condition ”), and such Condition is not waived in accordance with the terms of the SPA on or before the date that is 90 business days from the date of the SPA (such date as it may be extended under the terms of the SPA or as the parties may agree in writing, the “ Long Stop Date ”), or becomes incapable of satisfaction on or before the Long Stop Date, provided that each of the parties may in its sole discretion extend the Long Stop Date on no more than 2 occasions each and on each such occasion by up to 25 calendar days in the event that the Condition has not been satisfied prior to the Long Stop Date due to a breach by the other of its obligations under the SPA. Piper Sandler acted as exclusive financial advisor, and DLA Piper acted as legal counsel to Intercept.
Intercept Pharmaceuticals, Inc. - Shareholder/Analyst Call
2022-05-02 20:07:00
AGM
Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022
2022-05-02 20:07:00
Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022, at 12:00 US Eastern Standard Time. Agenda: To elect, by separate resolutions, the following eleven nominees to serve on our Board of Directors (the Board") until 2023 Annual Meeting or until their respective successors are duly elected and qualified; to approve amended and restated equity incentive plan; to approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers; to ratify the appointment of KPMG LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2022; and to transact such other business as may properly come before the meeting or any adjournments thereof.
Intercept Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 06, 2022
2022-05-02 12:00:00
Intercept Pharmaceuticals, Inc. announced that they will report Q1, 2022 results Pre-Market on May 06, 2022
Intercept Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 06, 2022
2022-05-02 12:00:00
Intercept Pharmaceuticals, Inc., Q1 2022 Earnings Call, May 06, 2022
The European Association for the Study of the Liver, the International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022
2022-03-30 21:14:00
The European Association for the Study of the Liver, The International Liver Congress 2022, Jun 22, 2022 through Jun 25, 2022. Venue: London, United Kingdom.
Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH
2021-12-20 13:00:00
Intercept Pharmaceuticals, Inc. announced that top-line data from its Phase 3 REVERSE trial will be delayed from previous guidance of near the end of the year and is now expected in the first quarter of 2022. REVERSE is the only active late-stage Phase 3 study in patients with compensated cirrhosis due to NASH, a serious disease for which there are no approved pharmacologic therapies. The liver biopsy samples from REVERSE are being evaluated utilizing a new consensus methodology. Intercept is also using this new methodology to compile a new data package from the Phase 3 REGENERATE study in liver fibrosis due to NASH for a potential resubmission meeting with FDA in the first half of 2022, if the data supports it. Results from REVERSE and REGENERATE represent the largest Phase 3 program ever conducted in liver fibrosis and compensated cirrhosis due to NASH.
Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH
2021-12-09 12:00:00
Intercept Pharmaceuticals, Inc. announced that it has formally notified the European Medicines Agency (EMA) of its decision to withdraw its Marketing Authorization Application (MAA) for obeticholic acid (OCA) for the treatment of liver fibrosis due to nonalcoholic steatohepatitis (NASH). The initial MAA filing in December 2019 was supported by the positive interim analysis results from the pivotal Phase 3 REGENERATE study which remains ongoing. Intercept is in the process of generating additional efficacy and safety data from REGENERATE, including a full reread of Month 18 biopsies using a new consensus biopsy reading approach, as well as a robust body of adjudicated safety data, to support a potential refiling in the U.S. As disclosed previously, Intercept has been working with the Committee for Medicinal Products for Human Use (CHMP) to potentially include this data in the current MAA review process. However, the established application timeline could not be extended any further to allow for submission of the additional data – which is expected in the early part of 2022 – and based on their review of data submitted to date, the CHMP was not able to determine a positive benefit-risk. As a result, the Company has made the decision to withdraw the MAA.
Intercept Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021
2021-11-22 15:06:00
Intercept Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference, Nov-29-2021 . Venue: New York, New York, United States.
Intercept Pharmaceuticals, Inc. Announces New Long-Term Data Demonstrating Potential of Obeticholic Acid to Improve Transplant-Free Survival in Patients with PBC
2021-11-15 13:00:00
Intercept Pharmaceuticals, Inc. announced results from a new analysis examining obeticholic acid’s (OCA) potential to improve transplant-free survival in patients with PBC. The data will be featured in a late-breaking podium presentation at The Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is being held virtually from November 12, 2021 to November 15, 2021. The POISE long-term safety extension (LTSE) study included 209 patients dosed with OCA with a maximum follow-up time of 6.3 years. Propensity score-matched external controls were patients from the Global PBC (n=1,391) and UK-PBC (n=2,138) real-world databases who were diagnosed with PBC and who met POISE clinical trial entry criteria. Patients from the external control databases were untreated or treated with ursodeoxycholic acid (UDCA) with at least one year of follow-up but were not treated with OCA or other therapies. The primary endpoint was time to liver transplantation or death. In this analysis, 209 patients treated with OCA in the POISE LTSE study had significantly great transplant-free survival than patients in the external control groups. In the OCA arm, three events were observed versus 146 and 276 events in the Global PBC and UK-PBC external control cohorts, respectively. In a weighted analysis, the hazard ratio favoring OCA was 0.20 (0.06-0.64, p=0.001) in Global PBC and 0.28 (0.09-0.90, p=0.033) in UK-PBC. Thus, patients treated with OCA had a 72% to 80% low risk of death or liver transplant than the control groups at any time during follow-up. Consistent findings were observed in multiple sensitivity analyses, as well as when testing for the influence of recruitment bias and potential confounding factors such as baseline bilirubin, ALP, AST or ALT, age, PBC duration, UDCA use, diagnosis year and sex.
Intercept Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM
2021-11-11 13:00:00
Intercept Pharmaceuticals, Inc. Presents at 12th Annual Jefferies Global Healthcare Conference, Nov-18-2021 03:00 AM. Venue: London, United Kingdom. Speakers: Andrew Saik, Chief Financial Officer, Jerry Durso, President and Chief Executive Officer, Linda M. Richardson, Executive VP & Chief Commercial Officer, M. Michelle Berrey, President of Research & Development and Chief Medical Officer.
Intercept Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM
2021-11-11 13:00:00
Intercept Pharmaceuticals, Inc. Presents at Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov-22-2021 10:00 AM.
Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022
2021-11-09 17:12:00
Biotechnology Innovation Organization, BIO International Convention 2022, Jun 13, 2022 through Jun 16, 2022. Venue: San Diego Convention Center, San Diego, California, United States.
Intercept Pharmaceuticals, Inc. Increases 2021 Financial Guidance
2021-11-03 11:00:00
Intercept Pharmaceuticals, Inc. increased 2021 Financial Guidance. The company increasing full year 2021 worldwide Ocaliva net sales guidance to $355 million to $370 million from $325 million to $340 million.
Intercept Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021
2021-10-27 12:00:00
Intercept Pharmaceuticals, Inc., Q3 2021 Earnings Call, Nov 03, 2021
Intercept Pharmaceuticals, Inc. to Report Q3, 2021 Results on Nov 03, 2021
2021-10-27 12:00:00
Intercept Pharmaceuticals, Inc. announced that they will report Q3, 2021 results Pre-Market on Nov 03, 2021
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021
2021-10-25 10:00:00
Piper Sandler Companies, Piper Sandler 33rd Annual Virtual Healthcare Conference: Fireside Chat, Nov 22, 2021.
Intercept Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $23.259665 million.
2021-09-29 00:00:00
Intercept Pharmaceuticals, Inc. has filed a Shelf Registration in the amount of $23.259665 million. Security Name: Common Stock Securities Offered: 1,473,063 Transaction Features: ESOP Related Offering
Intercept Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 08:40 AM
2021-09-21 12:00:00
Intercept Pharmaceuticals, Inc. Presents at Cantor Global Healthcare 2021 Conference, Sep-28-2021 08:40 AM. Venue: New York, United States. Speakers: Andrew Saik, Chief Financial Officer, Jerome B. Durso, President, CEO & Director, Linda M. Richardson, Executive VP & Chief Commercial Officer, M. Michelle Berrey, President of Research & Development and Chief Medical Officer.
Intercept Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 10:15 AM
2021-08-26 17:20:00
Intercept Pharmaceuticals, Inc. Presents at Baird Global Healthcare Conference 2021, Sep-14-2021 10:15 AM. Speakers: Andrew Saik, Chief Financial Officer, Jerry Durso, President, CEO, Lisa M. DeFrancesco, Senior VP of Corporate Affairs & Investor Relations, Michelle Berrey, President R&D, Chief Medical Officer.
Intercept Pharmaceuticals, Inc. announced that it has received $117.6 million in funding
2021-08-17 00:00:00
On August 17, 2021, Intercept Pharmaceuticals, Inc. closed the transaction. The notes will mature on February 15, 2026, unless earlier converted, redeemed or repurchased. The initial conversion rate is 47.7612 shares of the company’s common stock per $1,000 principal amount of Notes (equivalent to an initial conversion price of approximately $20.94 per share), subject to customary adjustments. The company may redeem for cash all or any portion of the notes, at its option, on or after February 20, 2024 if the last reported sale price of the company’s common stock has been at least 130% of the conversion price then in effect for at least 20 trading days (whether or not consecutive) during any 30 consecutive trading day period (including the last trading day of such period) ending on, and including, the trading day immediately preceding the date on which the company provides notice of redemption at a redemption price equal to 100% of the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021
2021-08-10 13:03:00
Robert W. Baird & Co. Incorporated, Baird Global Healthcare Conference 2021, Sep 14, 2021 through Sep 15, 2021.
Intercept Pharmaceuticals, Inc. announced that it expects to receive $117.6 million in funding
2021-08-10 00:00:00
Intercept Pharmaceuticals, Inc. announced that it has entered into subscription agreements for a private placement of 3.5% convertible senior secured notes due 2026 for gross proceeds of $117.6 million on August 10, 2021. The transaction will include participation from certain qualified investors who are both institutional accredited investors and qualified institutional buyers. The transaction is expected to close on or around August 17, 2021, subject to customary closing conditions. The notes will be convertible into cash, shares of the company’s common stock, par value $0.001 per share.
Intercept Pharmaceuticals, Inc. has announced a Fixed-Income Exchange Offer.
2021-08-10 00:00:00
Intercept Pharmaceuticals, Inc. has announced a Fixed-Income Exchange Offer. Security Name: 3.50% Senior Secured Notes due February 15, 2026 Security Type: Corporate Bond/Note (Convertible) Principal Amount: $382.4 million Security Features: Callable; Convertible Coupon Type: Fixed Transaction Features: Exchange Offer; Rule 144A
Intercept Pharmaceuticals, Inc. Reiterates Sales Guidance for the Full Year of 2021
2021-07-29 11:00:00
Intercept Pharmaceuticals, Inc. reiterated sales guidance for the full year of 2021. For the full year, the company is reiterating worldwide Ocaliva net sales guidance of $325 million to $340 million as the company monitor post-label update market dynamics.
Intercept Pharmaceuticals, Inc. to Report Q2, 2021 Results on Jul 29, 2021
2021-07-19 11:00:00
Intercept Pharmaceuticals, Inc. announced that they will report Q2, 2021 results Pre-Market on Jul 29, 2021
Intercept Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 29, 2021
2021-07-19 11:00:00
Intercept Pharmaceuticals, Inc., Q2 2021 Earnings Call, Jul 29, 2021
Fundamental Summary
Intercept Pharmaceuticals released impressive Q1 results on 2022-05-06. Their growth and income factors performance indicate that company management is focused on the right targets and executing well. This relative strength should allow Intercept Pharmaceuticals to continue to perform well even in a tough market. As such, Intercept Pharmaceuticals received an overall score of 78 and a HOLD recommendation.
Intercept Pharmaceuticals reported earnings results for the first quarter ended March 31, 2022. For the first quarter, the company reported revenue was USD 88.58 million compared to USD 81.66 million a year ago. Net loss was USD 17.28 million compared to USD 40.42 million a year ago. Basic loss per share from continuing operations was USD 0.58 compared to USD 1.22 a year ago. Diluted loss per share from continuing operations was USD 0.58 compared to USD 1.22 a year ago.
Business Description
Intercept Pharmaceuticals, a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in New York, New York.
Sector Overview
Intercept Pharmaceuticals is included in the Biotechnology according to GICS (global industry classification standard). The Biotechnology industry, which is part of the Health Care sector, includes companies primarily engaged in R&D, manufacturing, and/or marketing of products based on genetic analysis and genetic engineering. Intercept Pharmaceuticals's industry and sector affiliation are expected to negatively affect their likelihood to overperform the market in the upcoming period, as other sectors appear more likely to benefit from the macroeconomic environment we see now.
Fundamental Highlights
| Parameter | Value | Change | Score | |
|---|---|---|---|---|
| Return on Equity | 23.9 | -54.2% | 40 | |
| Net Cashflow | -40.9 | -242.3% | 87 | |
| Capital Expenditure | -0.0 | 93.2% | 98 | |
| Asset Turnover | 0.7 | 10.3% | 89 | |
| Free Cashflow | -0.2 | 82.5% | 95 |
* All values are TTM
The below chart reflects Intercept Pharmaceuticals's birds-eye view on its performance with respect to its peers, the company's fillings as reported or to a similar industry, market cap, and country of origin. While Intercept Pharmaceuticals's peer average final assessment score stands on 62.0, Intercept Pharmaceuticals's score is 78.
- ICPT
- Peers average
Technical Analysis
When trying to optimize the timing of an investment, it's critical to analyze whether the stock looks overbought or oversold, and in which direction the momentum is moving. Intercept Pharmaceuticals's stock is now priced below its 5-day, 50-day, and 200-day moving average, while its MACD (moving average convergence divergence) indicates that the stock's price movement momentum is weakening. Historically, this is a negative setup in the near, medium, and long-term. Meanwhile, looking at the Stochastic Oscillator and RSI (relative strength index), Intercept Pharmaceuticals's stock indicates that it's likely oversold. Overall, these technical indicators signal negative momentum. Therefore, this stock received a cumulative TA (technical analysis) score of 42.
5D MA
13.26
50D MA
15.82
200D MA
16.16
MACD
-0.97
RSI
20.86
STOCH
65.07
Balance Sheet Analysis
Intercept Pharmaceuticals's balance sheet factors had several troubling metrics this period. Intercept Pharmaceuticals's management did a relatively poor job managing cash and cash equivalents, which now sit at 48.3 and represents a -43.0% change from the last reporting period. The company's cash and cash equivalents metrics highlight a difficult overall financial situation, which may, unfortunately, continue moving forward unless management makes significant changes. Discouraging results like these statistically lead to negative pressure in stock prices, so we rated their cash and cash equivalents with a score of 41. Also, At filing, Intercept Pharmaceuticals's liabilities were 875.1, representing a 23.1% change from the previous period. This performance is relatively weak in comparison to their peers and suggests that its's stock price will likely suffer until this is solved. Its liabilities movement component, therefore, received a grade of 46. However, one encouraging metric, Assets, stood out. Intercept Pharmaceuticals's management was effective in managing the value of the assets on their balance sheet, which now sits at 503.4 and represents a -4.5% change from the previous report. This performance is interesting in comparison to its peers and competitors. The company's asset component, therefore, received a grade of 68. Because of these weaknesses, its balance sheet received an overall score of 57.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Assets | 503.4 | -4.5% | 68 |
| Liabilities | 875.1 | 23.1% | 46 |
| Price to Book | -1.4 | 45.6% | 61 |
| Cash & Equivalents | 48.3 | -43.0% | 41 |
| Equity | -371.8 | -102.1% | 57 |
The below chart describes Intercept Pharmaceuticals's performance as reflected on its balance sheet with respect to its peers. While Intercept Pharmaceuticals received a balance sheet score of 57, the average of its peers stands on 61.0.
- ICPT
- Peers average
| Name | Market Cap | Liabilities Movement | Asset Change | Equity/Intangibles Adjustments | Cash & Equivalents | Book Value Momentum | Balance Sheet | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 72 | 68 | 86 | 53 | 62 | 69 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 48 | 63 | 61 | 52 | 62 | 57 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 69 | 69 | 58 | 84 | 92 | 78 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 48 | 65 | 52 | 86 | 81 | 67 | 3 | 1 |
| BioNTech SE | 34.0B | 75 | 69 | 64 | 97 | 73 | 75 | 4 | 1 |
| Seagen Inc. | 32.9B | 59 | 68 | 55 | 43 | 66 | 61 | 5 | 1 |
| Biogen Inc. | 29.7B | 57 | 72 | 92 | 50 | 76 | 76 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 50 | 66 | 46 | 44 | 61 | 54 | 7 | 1 |
| Incyte Corporation | 16.8B | 71 | 72 | 95 | 82 | 79 | 83 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 55 | 75 | 54 | 77 | 74 | 70 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 61 | 74 | 58 | 60 | 88 | 76 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 67 | 69 | 55 | 51 | 78 | 68 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 53 | 66 | 57 | 84 | 81 | 70 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 68 | 69 | 49 | 41 | 58 | 58 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 59 | 68 | 65 | 72 | 85 | 74 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 59 | 68 | 58 | 43 | 67 | 62 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 51 | 70 | 85 | 94 | 54 | 68 | 16 | 1 |
| Alkermes plc | 5.0B | 63 | 66 | 46 | 54 | 71 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 49 | 79 | 42 | 76 | 62 | 64 | 18 | 1 |
| Novavax, Inc. | 4.0B | 61 | 67 | 52 | 77 | 99 | 77 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 53 | 66 | 57 | 48 | 42 | 50 | 20 | 1 |
| Natera, Inc. | 3.6B | 73 | 65 | 43 | 95 | 42 | 54 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 72 | 71 | 63 | 65 | 73 | 71 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 57 | 61 | 80 | 49 | 37 | 51 | 23 | 1 |
| Insmed Incorporated | 2.4B | 49 | 65 | 45 | 46 | 63 | 55 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 83 | 65 | 55 | 91 | 55 | 63 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 46 | 67 | 46 | 50 | 62 | 55 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 72 | 77 | 47 | 53 | 52 | 61 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 49 | 68 | 87 | 67 | 63 | 68 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 51 | 62 | 51 | 43 | 57 | 52 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 50 | 66 | 52 | 38 | 48 | 50 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 50 | 67 | 46 | 48 | 48 | 50 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 79 | 87 | 49 | 82 | 56 | 73 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 85 | 68 | 41 | 55 | 55 | 58 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 52 | 67 | 64 | 61 | 48 | 56 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 51 | 86 | 45 | 38 | 49 | 60 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 56 | 71 | 38 | 82 | 63 | 61 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 50 | 67 | 50 | 75 | 66 | 61 | 37 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 59 | 64 | 47 | 45 | 46 | 48 | 38 | 1 |
| AnaptysBio, Inc. | 586.3M | 85 | 63 | 41 | 37 | 51 | 52 | 39 | 1 |
| Geron Corporation | 566.2M | 69 | 72 | 37 | 59 | 62 | 60 | 40 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 75 | 68 | 39 | 82 | 52 | 58 | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 56 | 66 | 38 | 54 | 40 | 46 | 42 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 86 | 65 | 61 | 48 | 55 | 60 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 76 | 68 | 63 | 64 | 65 | 64 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 48 | 68 | 51 | 43 | 51 | 51 | 45 | 1 |
| Precigen, Inc. | 299.1M | 81 | 85 | 61 | 72 | 48 | 73 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 48 | 67 | 42 | 38 | 57 | 50 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 53 | 67 | 51 | 90 | 63 | 62 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 53 | 64 | 61 | 37 | 39 | 47 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 58 | 45 | 42 | 52 | 47 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 52 | 64 | 58 | 66 | 56 | 56 | 51 | 1 |
| CureVac N.V. | 2.6B | 49 | 64 | 75 | 52 | 52 | 57 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 63 | 70 | 54 | 39 | 45 | 53 | 53 | 1 |
| Abgenix Inc. | 2.1B | 81 | 57 | 86 | 92 | 45 | 67 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 48 | 69 | 53 | 45 | 70 | 61 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 52 | 74 | 72 | 87 | 45 | 63 | 56 | 1 |
| Xencor, Inc. | 1.6B | 53 | 78 | 60 | 40 | 67 | 67 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 48 | 62 | 87 | 48 | 61 | 61 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 52 | 69 | 54 | 38 | 76 | 63 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 75 | 63 | 61 | 49 | 52 | 56 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 51 | 67 | 59 | 41 | 47 | 52 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 64 | 68 | 54 | 66 | 51 | 57 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 62 | 71 | 52 | 97 | 97 | 80 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 48 | 69 | 61 | 44 | 57 | 57 | 64 | 1 |
| CareDx, Inc | 1.2B | 54 | 67 | 52 | 39 | 51 | 52 | 65 | 1 |
| Vericel Corporation | 1.1B | 51 | 65 | 56 | 53 | 61 | 57 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 75 | 61 | 61 | 58 | 72 | 67 | 67 | 1 |
| MannKind Corporation | 957.2M | 79 | 59 | 50 | 40 | 64 | 57 | 68 | 1 |
| Merus N.V. | 941.6M | 59 | 68 | 50 | 83 | 81 | 70 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 89 | 71 | 50 | 97 | 73 | 74 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 51 | 65 | 58 | 72 | 51 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 52 | 69 | 70 | 77 | 86 | 75 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 65 | 63 | 48 | 38 | 86 | 65 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 59 | 66 | 56 | 66 | 60 | 60 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 70 | 37 | 92 | 37 | 54 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 82 | 70 | 47 | 89 | 56 | 64 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 83 | 70 | 73 | 46 | 79 | 75 | 77 | 1 |
| Immatics N.V. | 538.7M | 56 | 70 | 84 | 95 | 73 | 76 | 78 | 1 |
| Agenus Inc. | 520.5M | 73 | 62 | 37 | 55 | 60 | 54 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 50 | 64 | 50 | 44 | 59 | 54 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 69 | 67 | 47 | 56 | 47 | 53 | 81 | 1 |
| Affimed N.V. | 415.0M | 56 | 66 | 63 | 56 | 47 | 54 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 74 | 68 | 49 | 77 | 72 | 68 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 53 | 66 | 42 | 57 | 37 | 45 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 48 | 65 | 42 | 58 | 62 | 54 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 76 | 68 | 61 | 78 | 60 | 66 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 77 | 69 | 70 | 90 | 43 | 62 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 84 | 65 | 48 | 43 | 58 | 58 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 58 | 71 | 69 | 63 | 59 | 66 | 89 | 1 |
| AC Immune SA | 299.8M | 84 | 64 | 47 | 53 | 75 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 56 | 72 | 44 | 37 | 76 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 82 | 69 | 56 | 66 | 49 | 61 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 48 | 63 | 46 | 95 | 40 | 49 | 93 | 1 |
| DermTech, Inc. | 165.3M | 76 | 72 | 51 | 52 | 43 | 56 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 47 | 76 | 48 | 76 | 98 | 78 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 37 | 71 | 45 | 39 | 55 | 49 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 48 | 70 | 44 | 90 | 37 | 43 | 97 | 1 |
Income Statement Analysis
Intercept Pharmaceuticals seems to be balancing strong EBITDA and Revenue Efficiency along with an overall impressive positive income statement. Intercept Pharmaceuticals reported impressive EBITDA this period. At filing, EBITDA was reported as -25.4, representing 41.4% change from the previous period. Companies in the same industry and market capitalization are typically affected by this parameter by up to 24.4%. Their EBITDA metrics are even more impressive relative to their peers and competitors, and its likely the stock price has room to grow to reflect its intrinsic value accurately. Therefore, its EBITDA component earned a score of 93. Also, Intercept Pharmaceuticals reported highly encouraging numbers for its revenue efficiency. This characteristic can affect companies in the same industry and market capitalization by up to 13.1%. Their impressive revenue efficiency is even more impressive relative to its peers and competitors in the current market. Consequently, their revenue efficiency received a grade of 71. However, one discouraging result, Return Factors, stood out. In this filing, Intercept Pharmaceuticals reported a return on equity (ROE) ratio of 23.9, which represents a growth of -54.2%. This metric might have a 3.6 percent impact on companies in the same industry and with the same market capitalization. The company's return factor metrics return on equity and return on assets are even more concerning when compared to their peers. Consequently, their return factors received a grade of 40. Because its management is doing an excellent job managing these critical metrics, the income statement was given a score of 86.
| Parameter | Value | Change | Score |
|---|---|---|---|
| EBITDA | -25.4 | 41.4% | 93 |
| Total Revenues | 370.4 | 1.9% | 71 |
| Return on Equity | 23.9 | -54.2% | 40 |
The below chart describes Intercept Pharmaceuticals's performance as reflected on its income statement with respect to its peers. While Intercept Pharmaceuticals received a income statement score of 86 , the average of its peers stands on 64.0.
- ICPT
- Peers average
| Name | Market Cap | Revenue Momentum | Earning Movement | Return Factors Momentum | Income Statement | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 74 | 75 | 64 | 78 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 78 | 71 | 52 | 73 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 57 | 80 | 62 | 75 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 67 | 74 | 66 | 74 | 3 | 1 |
| BioNTech SE | 34.0B | 41 | 89 | 75 | 79 | 4 | 1 |
| Seagen Inc. | 32.9B | 54 | 65 | 70 | 62 | 5 | 1 |
| Biogen Inc. | 29.7B | 90 | 57 | 73 | 70 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 60 | 86 | 56 | 80 | 7 | 1 |
| Incyte Corporation | 16.8B | 59 | 77 | 60 | 73 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 72 | 81 | 65 | 82 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 57 | 91 | 54 | 82 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 53 | 54 | 77 | 55 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 54 | 91 | 54 | 81 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 49 | 89 | 55 | 78 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 53 | 84 | 85 | 82 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 62 | 94 | 53 | 86 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 38 | 68 | 46 | 54 | 16 | 1 |
| Alkermes plc | 5.0B | 69 | 55 | 81 | 62 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 95 | 50 | 73 | 66 | 18 | 1 |
| Novavax, Inc. | 4.0B | 41 | 89 | 54 | 75 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 76 | 55 | 78 | 64 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 51 | 78 | 52 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 38 | 92 | 53 | 76 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 54 | 78 | 66 | 73 | 23 | 1 |
| Insmed Incorporated | 2.4B | 51 | 58 | 73 | 57 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 72 | 49 | 80 | 58 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 41 | 74 | 72 | 66 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 97 | 57 | 71 | 73 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 70 | 79 | 61 | 79 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 89 | 93 | 57 | 96 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 99 | 64 | 54 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 84 | 58 | 79 | 70 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 48 | 74 | 63 | 67 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 87 | 47 | 81 | 62 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 40 | 73 | 71 | 64 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 90 | 63 | 72 | 75 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 60 | 79 | 70 | 77 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 84 | 69 | 60 | 75 | 37 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 72 | 72 | 73 | 76 | 38 | 1 |
| AnaptysBio, Inc. | 586.3M | 97 | 50 | 77 | 68 | 39 | 1 |
| Geron Corporation | 566.2M | 89 | 67 | 73 | 78 | 40 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 37 | 54 | 72 | 47 | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 96 | 57 | 68 | 72 | 42 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 37 | 82 | 53 | 67 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 63 | 80 | 62 | 77 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 98 | 48 | 82 | 69 | 45 | 1 |
| Precigen, Inc. | 299.1M | 57 | 87 | 59 | 79 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 99 | 91 | 61 | 96 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 99 | 44 | 82 | 64 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 95 | 56 | 74 | 71 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 57 | 67 | 54 | 62 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 61 | 55 | 77 | 58 | 51 | 1 |
| CureVac N.V. | 2.6B | 45 | 83 | 71 | 74 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 45 | 52 | 61 | 46 | 53 | 1 |
| Abgenix Inc. | 2.1B | 47 | 47 | 47 | 47 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 41 | 65 | 59 | 56 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 84 | 60 | 75 | 71 | 56 | 1 |
| Xencor, Inc. | 1.6B | 42 | 94 | 52 | 79 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 91 | 51 | 77 | 66 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 51 | 69 | 77 | 67 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 92 | 53 | 78 | 69 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 38 | 81 | 68 | 70 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 45 | 63 | 57 | 55 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 84 | 54 | 54 | 61 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 96 | 53 | 78 | 70 | 64 | 1 |
| CareDx, Inc | 1.2B | 61 | 44 | 82 | 50 | 65 | 1 |
| Vericel Corporation | 1.1B | 76 | 44 | 82 | 56 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 49 | 82 | 69 | 75 | 67 | 1 |
| MannKind Corporation | 957.2M | 95 | 48 | 56 | 61 | 68 | 1 |
| Merus N.V. | 941.6M | 48 | 60 | 59 | 54 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 50 | 60 | 60 | 55 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 95 | 44 | 82 | 63 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 48 | 88 | 58 | 77 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 43 | 90 | 65 | 79 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 89 | 55 | 79 | 69 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 84 | 50 | 62 | 59 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 89 | 46 | 81 | 62 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 39 | 94 | 53 | 78 | 77 | 1 |
| Immatics N.V. | 538.7M | 37 | 93 | 53 | 77 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 83 | 45 | 74 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 94 | 71 | 68 | 82 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 99 | 51 | 72 | 68 | 81 | 1 |
| Affimed N.V. | 415.0M | 95 | 49 | 75 | 66 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 43 | 65 | 62 | 57 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 87 | 43 | 83 | 59 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 46 | 69 | 77 | 65 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 38 | 89 | 54 | 74 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 58 | 53 | 77 | 56 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 61 | 60 | 75 | 62 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 83 | 64 | 69 | 72 | 89 | 1 |
| AC Immune SA | 299.8M | 83 | 61 | 65 | 70 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 55 | 50 | 63 | 53 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 60 | 47 | 80 | 56 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 99 | 50 | 62 | 65 | 93 | 1 |
| DermTech, Inc. | 165.3M | 49 | 48 | 78 | 52 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 41 | 46 | 56 | 39 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 83 | 49 | 92 | 61 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 97 | 48 | 63 | 70 | 97 | 1 |
Cash Flow Analysis
Intercept Pharmaceuticals appears likely to maintain its strong cash flow metrics and momentum going forward. Intercept Pharmaceuticals's published capital expenditures (CapEx) numbers were encouraging and reflected management's balanced change strategy. Intercept Pharmaceuticals recorded CapEx of -0.0, which represents 93.2% change from the previous report. This remarkable CapEx growth is expected to reinforce upward momentum for its's stock price going forward. Consequently, their CapEx movement received a grade of 98. Also, Intercept Pharmaceuticals's published free cash flow numbers were substantial and reflected management's focus on a healthy change strategy. Intercept Pharmaceuticals recorded free cash flow of -0.2, which represents a 82.5% change from the previous report. Companies in the same industry and market capitalization are typically affected by this parameter by up to 2.6%. These free cash flow numbers show that management has executed well while generating cash flow and encouraging growth. Therefore, its free cash flow movement earned a score of 95. On the other hand, Net Cash Flow, jumped out as looking rather underwhelming. Intercept Pharmaceuticals's produced underwhelming cash flow numbers in this filing. Net cash flow was reported as -40.9, which is a -242.3% change from the last report. Intercept Pharmaceuticals's net cash flow metrics are especially disappointing relative to their peers. Hence, their net cash flow earned a score of 87. Because its management is doing an excellent job managing these critical metrics, the cash flow was given a score of 96.
| Parameter | Value | Change | Score |
|---|---|---|---|
| Net Cashflow | -40.9 | -242.3% | 87 |
| Capital Expenditure | -0.0 | 93.2% | 98 |
| Asset Turnover | 0.7 | 10.3% | 89 |
| Free Cashflow | -0.2 | 82.5% | 95 |
The below chart describes Intercept Pharmaceuticals's performance as reflected on its cash flow with respect to its peers. While Intercept Pharmaceuticals received a cash flow score of 96, the average of its peers stands on 70.0.
- ICPT
- Peers average
| Name | Market Cap | Cashflow Momentum | Free Cashflow Growth | Capital Expenditure Growth | Assets Factors Momentum | Cash Flow | mc_sort | Hidden |
|---|---|---|---|---|---|---|---|---|
| Amgen Inc. | 130.1B | 80 | 74 | 67 | 74 | 81 | 0 | 1 |
| Gilead Sciences, Inc. | 78.0B | 57 | 61 | 53 | 85 | 62 | 1 | 1 |
| Vertex Pharmaceuticals Incorporated | 70.6B | 64 | 75 | 80 | 71 | 71 | 2 | 1 |
| Regeneron Pharmaceuticals, Inc. | 64.0B | 69 | 86 | 64 | 66 | 73 | 3 | 1 |
| BioNTech SE | 34.0B | 73 | 97 | 50 | 52 | 72 | 4 | 1 |
| Seagen Inc. | 32.9B | 53 | 53 | 50 | 87 | 58 | 5 | 1 |
| Biogen Inc. | 29.7B | 58 | 54 | 90 | 73 | 66 | 6 | 1 |
| Alnylam Pharmaceuticals, Inc. | 17.2B | 82 | 80 | 70 | 89 | 85 | 7 | 1 |
| Incyte Corporation | 16.8B | 78 | 79 | 92 | 74 | 84 | 8 | 1 |
| BioMarin Pharmaceutical Inc. | 15.4B | 59 | 48 | 66 | 77 | 63 | 9 | 1 |
| United Therapeutics Corporation | 10.6B | 93 | 92 | 68 | 80 | 93 | 10 | 1 |
| Neurocrine Biosciences, Inc. | 9.3B | 63 | 43 | 54 | 74 | 63 | 11 | 1 |
| Exelixis, Inc. | 6.7B | 79 | 90 | 89 | 83 | 87 | 12 | 1 |
| Sarepta Therapeutics, Inc. | 6.5B | 85 | 89 | 95 | 87 | 93 | 13 | 1 |
| Halozyme Therapeutics, Inc. | 6.3B | 83 | 66 | 52 | 49 | 75 | 14 | 1 |
| Ionis Pharmaceuticals, Inc. | 5.4B | 88 | 96 | 60 | 86 | 89 | 15 | 1 |
| Ascendis Pharma A/S | 5.2B | 48 | 59 | 77 | 98 | 62 | 16 | 1 |
| Alkermes plc | 5.0B | 89 | 95 | 76 | 80 | 92 | 17 | 1 |
| Cytokinetics, Incorporated | 4.1B | 63 | 79 | 89 | 51 | 69 | 18 | 1 |
| Novavax, Inc. | 4.0B | 62 | 38 | 63 | 54 | 60 | 19 | 1 |
| Mirati Therapeutics, Inc. | 3.8B | 56 | 58 | 71 | 89 | 65 | 20 | 1 |
| Natera, Inc. | 3.6B | 52 | 54 | 56 | 84 | 58 | 21 | 1 |
| Arrowhead Pharmaceuticals, Inc. | 3.4B | 60 | 39 | 87 | 96 | 70 | 22 | 1 |
| PTC Therapeutics, Inc. | 2.8B | 72 | 53 | 54 | 83 | 72 | 23 | 1 |
| Insmed Incorporated | 2.4B | 79 | 80 | 61 | 89 | 82 | 24 | 1 |
| ACADIA Pharmaceuticals Inc. | 2.3B | 61 | 57 | 98 | 80 | 72 | 25 | 1 |
| BioCryst Pharmaceuticals, Inc. | 1.9B | 61 | 58 | 54 | 96 | 67 | 26 | 1 |
| ChemoCentryx, Inc. | 1.8B | 84 | 92 | 97 | 50 | 87 | 27 | 1 |
| Ironwood Pharmaceuticals, Inc. | 1.8B | 77 | 66 | 67 | 76 | 78 | 28 | 1 |
| Myriad Genetics, Inc. | 1.5B | 50 | 37 | 82 | 83 | 59 | 29 | 1 |
| Agios Pharmaceuticals, Inc. | 1.2B | 85 | 68 | 44 | 46 | 75 | 30 | 1 |
| IVERIC bio, Inc. | 1.1B | 64 | 67 | 44 | 71 | 64 | 31 | 1 |
| FibroGen, Inc. | 1.0B | 86 | 74 | 48 | 87 | 84 | 32 | 1 |
| Syndax Pharmaceuticals, Inc. | 1.0B | 50 | 41 | 74 | 78 | 57 | 33 | 1 |
| ImmunoGen, Inc. | 946.1M | 77 | 79 | 95 | 95 | 87 | 34 | 1 |
| Enanta Pharmaceuticals, Inc. | 922.8M | 58 | 47 | 84 | 83 | 66 | 35 | 1 |
| Deciphera Pharmaceuticals, Inc. | 914.0M | 87 | 79 | 95 | 91 | 94 | 36 | 1 |
| Anavex Life Sciences Corp. | 767.1M | 69 | 63 | 74 | 71 | 72 | 37 | 1 |
| Sangamo Therapeutics, Inc. | 600.0M | 85 | 78 | 93 | 83 | 91 | 38 | 1 |
| AnaptysBio, Inc. | 586.3M | 80 | 77 | 92 | 41 | 80 | 39 | 1 |
| Geron Corporation | 566.2M | 78 | 68 | 49 | 81 | 77 | 40 | 1 |
| Mersana Therapeutics, Inc. | 449.1M | 59 | 69 | 53 | 92 | 65 | 41 | 1 |
| Inovio Pharmaceuticals, Inc. | 416.9M | 67 | 67 | 92 | 44 | 71 | 42 | 1 |
| Arbutus Biopharma Corporation | 388.2M | 92 | 93 | 80 | 87 | 95 | 43 | 1 |
| Anika Therapeutics, Inc. | 322.7M | 69 | 67 | 70 | 51 | 63 | 44 | 1 |
| Lexicon Pharmaceuticals, Inc. | 321.6M | 91 | 82 | 39 | 46 | 77 | 45 | 1 |
| Precigen, Inc. | 299.1M | 82 | 75 | 37 | 85 | 74 | 46 | 1 |
| bluebird bio, Inc. | 288.7M | 89 | 77 | 93 | 37 | 83 | 47 | 1 |
| Rigel Pharmaceuticals, Inc. | 187.5M | 42 | 40 | 46 | 40 | 41 | 48 | 1 |
| MacroGenics, Inc. | 184.6M | 70 | 53 | 54 | 46 | 65 | 49 | 1 |
| Exact Sciences Corporation | 7.2B | 53 | 45 | 80 | 46 | 56 | 50 | 1 |
| Amicus Therapeutics, Inc. | 3.0B | 81 | 80 | 71 | 87 | 85 | 51 | 1 |
| CureVac N.V. | 2.6B | 87 | 80 | 90 | 70 | 90 | 52 | 1 |
| Fate Therapeutics, Inc. | 2.4B | 64 | 52 | 55 | 48 | 61 | 53 | 1 |
| Abgenix Inc. | 2.1B | 66 | 53 | 45 | 59 | 58 | 54 | 1 |
| Xenon Pharmaceuticals Inc. | 1.9B | 82 | 77 | 87 | 92 | 89 | 55 | 1 |
| Iovance Biotherapeutics, Inc. | 1.7B | 77 | 66 | 69 | 69 | 77 | 56 | 1 |
| Xencor, Inc. | 1.6B | 96 | 95 | 70 | 95 | 98 | 57 | 1 |
| Emergent BioSolutions Inc. | 1.6B | 70 | 53 | 87 | 75 | 75 | 58 | 1 |
| Dynavax Technologies Corporation | 1.5B | 64 | 48 | 82 | 65 | 68 | 59 | 1 |
| Ligand Pharmaceuticals Incorporated | 1.5B | 86 | 93 | 51 | 78 | 84 | 60 | 1 |
| Aurinia Pharmaceuticals Inc. | 1.4B | 73 | 79 | 92 | 96 | 84 | 61 | 1 |
| Veracyte, Inc. | 1.4B | 90 | 95 | 46 | 46 | 82 | 62 | 1 |
| Sierra Oncology, Inc. | 1.3B | 47 | 77 | 38 | 71 | 52 | 63 | 1 |
| Celldex Therapeutics, Inc. | 1.3B | 69 | 63 | 67 | 54 | 69 | 64 | 1 |
| CareDx, Inc | 1.2B | 98 | 84 | 40 | 50 | 86 | 65 | 1 |
| Vericel Corporation | 1.1B | 64 | 46 | 59 | 73 | 65 | 66 | 1 |
| Avid Bioservices, Inc. | 959.5M | 80 | 38 | 40 | 50 | 66 | 67 | 1 |
| MannKind Corporation | 957.2M | 77 | 56 | 43 | 37 | 66 | 68 | 1 |
| Merus N.V. | 941.6M | 70 | 71 | 74 | 53 | 71 | 69 | 1 |
| Sorrento Therapeutics, Inc. | 747.5M | 48 | 63 | 61 | 52 | 52 | 70 | 1 |
| Amarin Corporation plc | 734.5M | 52 | 40 | 74 | 55 | 55 | 71 | 1 |
| Catalyst Pharmaceuticals, Inc. | 707.1M | 77 | 81 | 98 | 87 | 87 | 72 | 1 |
| Northwest Biotherapeutics, Inc. | 682.9M | 80 | 77 | 81 | 86 | 85 | 73 | 1 |
| Organogenesis Holdings Inc. | 612.1M | 76 | 76 | 63 | 55 | 75 | 74 | 1 |
| CTI BioPharma Corp. | 603.6M | 48 | 60 | 74 | 67 | 56 | 75 | 1 |
| Vanda Pharmaceuticals Inc. | 598.8M | 66 | 60 | 87 | 51 | 69 | 76 | 1 |
| Eagle Pharmaceuticals, Inc. | 546.4M | 63 | 40 | 97 | 92 | 73 | 77 | 1 |
| Immatics N.V. | 538.7M | 82 | 95 | 56 | 99 | 86 | 78 | 1 |
| Agenus Inc. | 520.5M | 57 | 43 | 52 | 77 | 58 | 79 | 1 |
| Radius Health, Inc. | 499.8M | 64 | 40 | 37 | 56 | 57 | 80 | 1 |
| Vaxart, Inc. | 440.0M | 72 | 56 | 53 | 38 | 65 | 81 | 1 |
| Affimed N.V. | 415.0M | 72 | 57 | 95 | 43 | 74 | 82 | 1 |
| ADMA Biologics, Inc. | 396.6M | 62 | 77 | 74 | 85 | 71 | 83 | 1 |
| MiMedx Group, Inc. | 391.5M | 46 | 48 | 97 | 86 | 60 | 84 | 1 |
| Albireo Pharma, Inc. | 362.9M | 59 | 68 | 41 | 95 | 63 | 85 | 1 |
| AVEO Pharmaceuticals, Inc. | 337.5M | 94 | 87 | 74 | 83 | 95 | 86 | 1 |
| Zymeworks Inc. | 324.7M | 52 | 65 | 45 | 83 | 57 | 87 | 1 |
| Heron Therapeutics, Inc. | 314.6M | 66 | 74 | 61 | 84 | 71 | 88 | 1 |
| Silence Therapeutics plc | 313.4M | 68 | 66 | 72 | 69 | 69 | 89 | 1 |
| AC Immune SA | 299.8M | 66 | 77 | 79 | 63 | 68 | 90 | 1 |
| Viridian Therapeutics, Inc. | 293.2M | 72 | 87 | 43 | 45 | 65 | 91 | 1 |
| Sutro Biopharma, Inc. | 245.5M | 83 | 67 | 64 | 50 | 74 | 92 | 1 |
| Chimerix, Inc. | 178.4M | 80 | 84 | 95 | 47 | 83 | 93 | 1 |
| DermTech, Inc. | 165.3M | 60 | 51 | 45 | 86 | 58 | 94 | 1 |
| Gelesis Holdings, Inc. | 111.5M | 64 | 90 | 92 | 98 | 80 | 95 | 1 |
| Brooklyn ImmunoTherapeutics, Inc. | 31.8M | 58 | 72 | 43 | 71 | 58 | 96 | 1 |
| INSYS Therapeutics, Inc. | 3.2M | 75 | 78 | 87 | 52 | 73 | 97 | 1 |
This report is intended for general guidance and information purposes only and under no circumstances is tailored to a specific factor or variable related to its reader or intended to be used or considered as financial or investment advice, a solicitation of any offer, a recommendation, or an offer to sell or buy any securities or other form of a financial asset. For the full disclaimer, click here.